News of Note—European Commission, Sinovac drama and more

In this week's news of note, Vaccines Europe urges the European Commission to play a more active role in ensuring vaccines supply. (Pixabay)

Here is some other vaccine news of note for the week.

> The European Commission could play a more active role in improving the regulatory framework for vaccines to avoid supply issues, according to the European vaccine industry group Vaccines Europe. Euractiv article

> Chinese vaccine maker Sinovac accused Sinobioway and "dozens of unnamed individuals" of trying to take over its manufacturing site, including by cutting power there multiple times and preventing employees from getting to their work stations. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Advaxis, which develops neoantigen cancer vaccines, hired former Rosetta Genomics chief Kenneth Berlin to fill its vacant CEO post, among other executive moves. FierceBiotech article

> The Sabin Vaccine Institute awarded Paul Offit, M.D., the 2018 Albert B. Sabin Gold Medal for his work in co-inventing oral rotavirus vaccine RotaTeq and leading advocacy for immunization. Release

> Celldex, the developer of failed cancer vaccine Rintega, is laying off 20% of its workforce. FierceBiotech article.

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.